Jupiter, Florida – October 16, 2026 -- Myosin Therapeutics will present its first-in-class cancer candidate MT-125 at BioFuture 2026 in New York City on October 27–28, seeking investors and pharmaceutical partners to fund an extension into two additional treatment-resistant cancers.

Jupiter, Florida – September 19, 2026 -- Myosin Therapeutics, Inc. has been selected as one of just 30 companies for the National Cancer Institute's 2026–2027 Investor Initiatives Showcase, a distinction drawn from NCI's full portfolio of funded companies following a competitive review by more than 70 third-party investors and strategic partners.